There was quite a bit of discussion at the October ACIP meeting about the exciting advancements in preventing invasive pneumococcal disease in adults!
The CDC’s Advisory Committee on Immunization Practices (ACIP) now recommends a pneumococcal conjugate vaccine (PCV) for all PCV-naive adults aged 50 years or older.
As announced previously, Merck’s Capvaxive™ Vaccine (PCV21) is now a part of the portfolio of discounts available to CPP members who are enrolled in the Merck contract. Please refer to Merck’s press release regarding the ACIP’s recommendation as well as their billing and coding guide for additional information.
CPP Merck Discount
If you have questions about the member discounts or if you would like to enroll in the Merck contract, please contact the CPP office.